Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n = 70) and Phase II (n = 53) of the MenAfriVac introduction campaign, Niamey and Tillabéri, Niger, September–December 2010.

Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

Kristiansen, Paul Arne
Ba, Absatou Ky
Ouédraogo, Abdoul-Salam
Sanou, Idrissa
Ouédraogo, Rasmata
Sangaré, Lassana
Diomandé, Fabien
Kandolo, Denis
Saga, Inger Marie
Misegades, Lara
Clark, Thomas A.
Préziosi, Marie-Pierre
Caugant, Dominique A

January 2014

Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is c...

1Pan African Medical Journal. 2014;18(Supp 1):10 | Abdulaziz Mohammed et al. Characteristics of persons refusing oral polio vaccine

Abdulaziz Mohammed
Kabir Sabitu
Patrick Nguku
Emmanuel Abanida
Sadik Sheidu
Mahmood Dalhat
Raymond Dankoli
Saheed Gidado
Idris Suleiman

January 2011

Introduction: Nigeria, the only African country endemic for wild poliovirus, adopted Immunization Pl...

Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt

Chippaux, Jean-Philippe
Campagne, G.
Djibo, S.
Cissé, L.
Hassane, A.
Kanta, I.

January 1999

Control of meningitis epidemics is based on early case detection followed by mass campaigns of immun...

Reason for non-vaccination among individuals not vaccinated, Boffa and Forécariah prefectures, April–June 2012.

Francisco J. Luquero (121649)
Lise Grout (473305)
Iza Ciglenecki (446458)
Keita Sakoba (4858897)
Bala Traore (473306)
Melat Heile (456522)
Alpha Amadou Dialo (473307)
Christian Itama (456523)
Micaela Serafini (473308)
Dominique Legros (267127)
Rebecca F. Grais (38515)

October 2013

Reason for non-vaccination among individuals not vaccinated, Boffa and Forécariah prefectures, Ap...

Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.

Sung Hye Kim
Lorenzo Pezzoli
Harouna Yacouba
Tiekoura Coulibaly
Mamoudou H Djingarey
William A Perea
Thomas F Wierzba

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the A...

Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the MenAfriVac introduction campaign presented by administrative coverage and Lot Quality Assurance (LQA) analysis, Filingue, Niger, October 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the Men...

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by administrative coverage and coverage survey results, Niger, October–December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by admini...

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac introduction by administrative methods and Clustered Lot Quality Assurance Sampling (CLQAS) survey, Niamey and Tillabéri, Niger, December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac in...

Reasons for non-vaccination of children (N = 328) in school during mass vaccination campaign in El Nido elementary schools, January and February 2012.

Raffy Deray (730879)
Cesar Rivera (4729647)
Shiela Gripon (730880)
Corazon Ulanday (730881)
Maria Concepcion Roces (650332)
Anna Charinna Amparo (4729644)
Michael Attlan (4729650)
Clarisse Demont (730882)
Alexia Kieffer (404247)
Mary Elizabeth Miranda (725082)

January 2018

Reasons for non-vaccination of children (N = 328) in school during mass vaccination campaign in E...

Major reasons for rejecting pH1N1 vaccination among respondents who reported not receiving pH1N1 vaccination.

Qiuyan Liao (239966)
Benjamin J. Cowling (91306)
Wendy Wing Tak Lam (354799)
Richard Fielding (239990)

February 2013

Major reasons for rejecting pH1N1 vaccination among respondents who reported not receiving pH1N1 ...

Reasons for not receiving the influenza vaccination and the willingness of vaccination in 2016–17.

Lili Xu (257856)
Ying Qin (730676)
Juan Yang (384075)
Wei Han (151406)
Youju Lei (4281106)
Huaxiang Feng (4281103)
Xiaoyun Zhu (187050)
Yanming Li (145698)
Hongjie Yu (16137)
Luzhao Feng (376868)
Yan Shi (166398)

July 2017

(A) Reasons for vaccination. (B) Reasons for non-vaccination. (C) The willingness of vaccination ...

Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon

Ateudjieu, Jerome
Stoll, Beat
Nguefack-Tsague, Georges
Yakum, Martin Ndinakie
Mengouo, Marcellin Nimpa
Genton, Blaise

January 2016

A new vaccine against meningitis A was introduced in Africa meningitis belt in 2010. This study was ...

Causes de non vaccination et d’abandon vaccinal en zone urbaine a Lome (Togo)

Guedehoussou, T
Djinadou, MG
Atakouma, NK
Tatagan-Agbi, K
Assimadi, JK

August 2016

Les auteurs ont réalisé du 1er au 30 Août 2006 une étude dans le troisième district sanitaire de Lom...

Reasons for non-vaccination and awareness of the phase 2 measles vaccination campaign by urban and rural areas, Jharkhand, 2012.

Heather M. Scobie (42987)
Arindam Ray (745255)
Satyabrata Routray (563442)
Anindya Bose (745256)
Sunil Bahl (563445)
Stephen Sosler (640845)
Kathleen Wannemuehler (355555)
Rakesh Kumar (8432)
Pradeep Haldar (745257)
Abhijeet Anand (745258)

May 2015

Abbreviations: ASHA = accredited social health activist, AWW = anganwadi workers, ANM = auxiliary...

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A

Meningococcal Conjugate Vaccine (psa-tt
Neal A. Halsey

August 2016

Background. The monovalent meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed for ...

Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

Kristiansen, Paul Arne
Ba, Absatou Ky
Ouédraogo, Abdoul-Salam
Sanou, Idrissa
Ouédraogo, Rasmata
Sangaré, Lassana
Diomandé, Fabien
Kandolo, Denis
Saga, Inger Marie
Misegades, Lara
Clark, Thomas A.
Préziosi, Marie-Pierre
Caugant, Dominique A

January 2014

Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is c...

1Pan African Medical Journal. 2014;18(Supp 1):10 | Abdulaziz Mohammed et al. Characteristics of persons refusing oral polio vaccine

Abdulaziz Mohammed
Kabir Sabitu
Patrick Nguku
Emmanuel Abanida
Sadik Sheidu
Mahmood Dalhat
Raymond Dankoli
Saheed Gidado
Idris Suleiman

January 2011

Introduction: Nigeria, the only African country endemic for wild poliovirus, adopted Immunization Pl...

Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt

Chippaux, Jean-Philippe
Campagne, G.
Djibo, S.
Cissé, L.
Hassane, A.
Kanta, I.

January 1999

Control of meningitis epidemics is based on early case detection followed by mass campaigns of immun...

Reason for non-vaccination among individuals not vaccinated, Boffa and Forécariah prefectures, April–June 2012.

Francisco J. Luquero (121649)
Lise Grout (473305)
Iza Ciglenecki (446458)
Keita Sakoba (4858897)
Bala Traore (473306)
Melat Heile (456522)
Alpha Amadou Dialo (473307)
Christian Itama (456523)
Micaela Serafini (473308)
Dominique Legros (267127)
Rebecca F. Grais (38515)

October 2013

Reason for non-vaccination among individuals not vaccinated, Boffa and Forécariah prefectures, Ap...

Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.

Sung Hye Kim
Lorenzo Pezzoli
Harouna Yacouba
Tiekoura Coulibaly
Mamoudou H Djingarey
William A Perea
Thomas F Wierzba

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the A...

Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the MenAfriVac introduction campaign presented by administrative coverage and Lot Quality Assurance (LQA) analysis, Filingue, Niger, October 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the Men...

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by administrative coverage and coverage survey results, Niger, October–December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by admini...

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac introduction by administrative methods and Clustered Lot Quality Assurance Sampling (CLQAS) survey, Niamey and Tillabéri, Niger, December 2010.

Sung Hye Kim (334729)
Lorenzo Pezzoli (334731)
Harouna Yacouba (334732)
Tiekoura Coulibaly (334733)
Mamoudou H. Djingarey (334734)
William A. Perea (334735)
Thomas F. Wierzba (111421)

February 2013

Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac in...

Reasons for non-vaccination of children (N = 328) in school during mass vaccination campaign in El Nido elementary schools, January and February 2012.

Raffy Deray (730879)
Cesar Rivera (4729647)
Shiela Gripon (730880)
Corazon Ulanday (730881)
Maria Concepcion Roces (650332)
Anna Charinna Amparo (4729644)
Michael Attlan (4729650)
Clarisse Demont (730882)
Alexia Kieffer (404247)
Mary Elizabeth Miranda (725082)

January 2018

Reasons for non-vaccination of children (N = 328) in school during mass vaccination campaign in E...

Major reasons for rejecting pH1N1 vaccination among respondents who reported not receiving pH1N1 vaccination.

Qiuyan Liao (239966)
Benjamin J. Cowling (91306)
Wendy Wing Tak Lam (354799)
Richard Fielding (239990)

February 2013

Major reasons for rejecting pH1N1 vaccination among respondents who reported not receiving pH1N1 ...

Reasons for not receiving the influenza vaccination and the willingness of vaccination in 2016–17.

Lili Xu (257856)
Ying Qin (730676)
Juan Yang (384075)
Wei Han (151406)
Youju Lei (4281106)
Huaxiang Feng (4281103)
Xiaoyun Zhu (187050)
Yanming Li (145698)
Hongjie Yu (16137)
Luzhao Feng (376868)
Yan Shi (166398)

July 2017

(A) Reasons for vaccination. (B) Reasons for non-vaccination. (C) The willingness of vaccination ...

Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon

Ateudjieu, Jerome
Stoll, Beat
Nguefack-Tsague, Georges
Yakum, Martin Ndinakie
Mengouo, Marcellin Nimpa
Genton, Blaise

January 2016

A new vaccine against meningitis A was introduced in Africa meningitis belt in 2010. This study was ...

Causes de non vaccination et d’abandon vaccinal en zone urbaine a Lome (Togo)

Guedehoussou, T
Djinadou, MG
Atakouma, NK
Tatagan-Agbi, K
Assimadi, JK

August 2016

Les auteurs ont réalisé du 1er au 30 Août 2006 une étude dans le troisième district sanitaire de Lom...

Reasons for non-vaccination and awareness of the phase 2 measles vaccination campaign by urban and rural areas, Jharkhand, 2012.

Heather M. Scobie (42987)
Arindam Ray (745255)
Satyabrata Routray (563442)
Anindya Bose (745256)
Sunil Bahl (563445)
Stephen Sosler (640845)
Kathleen Wannemuehler (355555)
Rakesh Kumar (8432)
Pradeep Haldar (745257)
Abhijeet Anand (745258)

May 2015

Abbreviations: ASHA = accredited social health activist, AWW = anganwadi workers, ANM = auxiliary...

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A

Meningococcal Conjugate Vaccine (psa-tt
Neal A. Halsey

August 2016

Background. The monovalent meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed for ...

Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

Kristiansen, Paul Arne
Ba, Absatou Ky
Ouédraogo, Abdoul-Salam
Sanou, Idrissa
Ouédraogo, Rasmata
Sangaré, Lassana
Diomandé, Fabien
Kandolo, Denis
Saga, Inger Marie
Misegades, Lara
Clark, Thomas A.
Préziosi, Marie-Pierre
Caugant, Dominique A

January 2014

Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is c...

1Pan African Medical Journal. 2014;18(Supp 1):10 | Abdulaziz Mohammed et al. Characteristics of persons refusing oral polio vaccine

Abdulaziz Mohammed
Kabir Sabitu
Patrick Nguku
Emmanuel Abanida
Sadik Sheidu
Mahmood Dalhat
Raymond Dankoli
Saheed Gidado
Idris Suleiman

January 2011

Introduction: Nigeria, the only African country endemic for wild poliovirus, adopted Immunization Pl...

Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt

Chippaux, Jean-Philippe
Campagne, G.
Djibo, S.
Cissé, L.
Hassane, A.
Kanta, I.

January 1999

Control of meningitis epidemics is based on early case detection followed by mass campaigns of immun...

Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n = 70) and Phase II (n = 53) of the MenAfriVac introduction campaign, Niamey and Tillabéri, Niger, September–December 2010.

Abstract

Extracted data

Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n = 70) and Phase II (n = 53) of the MenAfriVac introduction campaign, Niamey and Tillabéri, Niger, September–December 2010.

Abstract

Extracted data

Related items

Related items